HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
VBIO
Valion Bio, Inc.
There isn't enough reported data to score VBIO yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
VBIO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Unavailable |
VBIO's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
VBIO PE Valuation
VBIO has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
VBIO Forward outlook
There aren't enough analyst estimates for VBIO to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
VBIO Earnings Per Share
VBIO and HIMS do not have enough comparable growth data to identify a winner.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus up 16% for VBIO.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
VBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $146K | +16% |
| Q2 2025 | $86K | -39% |
| Q1 2025 | $70K | -79% |
| Q4 2024 | $180K | -50% |
| Q3 2024 | $126K | -55% |
| Q2 2024 | $140K | -13% |
| Q1 2024 | $334K | -11% |
| Q4 2023 | $357K | -13% |
VBIO's revenue is recovering but still below its 2022 peak: $146,000 last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -1701% | -565 points |
| Q2 2025 | -2249% | -1387 points |
| Q1 2025 | -2151% | -1708 points |
| Q4 2024 | -857% | -229 points |
| Q3 2024 | -1136% | -512 points |
| Q2 2024 | -861% | +459 points |
| Q1 2024 | -443% | +119 points |
| Q4 2023 | -629% | -76 points |
VBIO's operating margin was −1701% last quarter, down 565 points from the same quarter a year ago, near the bottom of its range since 2020.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the stronger cash trend. Its trailing FCF is down 84% versus its history, compared with VBIO at down 115%.
VBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$5M | -$4.1M |
| Q4 2023 | -$1.8M | +$453K |
| Q3 2023 | -$1.9M | +$906K |
| Q4 2022 | -$2.2M | +$533K |
| Q3 2022 | -$2.8M | -$1.1M |
| Q4 2021 | -$2.8M | -$2.2M |
| Q3 2021 | -$1.6M | -$1.1M |
| Q2 2021 | -$543K | +$115K |
VBIO has burned cash in almost every quarter: −$15M over the past year, against −$7M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over VBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
VBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +17% | +19.9K shares |
| 1 year | +467% | +111K shares |
VBIO has 135,200 diluted shares, up 467% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
VBIO Net Leverage
VBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
VBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.0 | Oversold |
| Stochastic | 0.1 | Oversold |
VBIO's weekly RSI is 22 (oversold) and its Stochastic is 0 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
VBIO PE vs Healthcare Sector
VBIO has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
VBIO has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus VBIO above 0 of 3.
VBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.43 | 64% below |
| 20 week MA | $4.48 | 89% below |
| 50 week MA | $17.8 | 97% below |
VBIO is in a downtrend: it's below all three of its weekly moving averages, and 97% below its 50-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over VBIO on returns for 2026, with the stronger performance.
VBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $93.0 | $40.3 | -57% |
| 2026 YTD | $40.3 | $0.51 | -99% |
VBIO has finished every year since 2025 lower, and it's down 99% so far in 2026.